KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Thermo Fisher Scientific (TMO) Work In Process (2023 - 2025)

Thermo Fisher Scientific's Work In Process history spans 10 years, with the latest figure at $889.0 million for Q4 2025.

  • For the quarter ending Q4 2025, Work In Process rose 17.75% year-over-year to $889.0 million, compared with a TTM value of $889.0 million through Dec 2025, up 17.75%, and an annual FY2025 reading of $889.0 million, up 17.75% over the prior year.
  • Work In Process for Q4 2025 was $889.0 million at Thermo Fisher Scientific, down from $990.0 million in the prior quarter.
  • The five-year high for Work In Process was $990.0 million in Q3 2025, with the low at $705.0 million in Q4 2023.
  • Average Work In Process over 3 years is $860.0 million, with a median of $881.5 million recorded in 2025.
  • Year-over-year, Work In Process rose 7.09% in 2024 and then rose 17.75% in 2025.
  • Tracing TMO's Work In Process over 3 years: stood at $705.0 million in 2023, then increased by 7.09% to $755.0 million in 2024, then increased by 17.75% to $889.0 million in 2025.
  • Per Business Quant, the three most recent readings for TMO's Work In Process are $889.0 million (Q4 2025), $990.0 million (Q3 2025), and $947.0 million (Q2 2025).